Table 1.
Baseline characteristics, (N = 304) (immunocompromised conditions, n = 167a; Down syndrome, n = 138a)
| Characteristics | n (%)b |
|---|---|
| Gender | |
| Male | 187 (61.5) |
| Female | 117 (38.5) |
| Race | |
| Japanese | 297 (97.7) |
| Asian, non-Japanese | 3 (1.0) |
| Other | 4 (1.3) |
| Age in months at the start of palivizumab administration | |
| N | 304 |
| Mean (SD) | 11.9 (7.5) |
| Median (min–max) | 11.5 (0–24) |
| Gestational age in weeks | |
| N | 294 |
| Mean (SD) | 37.8 (2.0) |
| Median (min–max) | 38.0 (28–42) |
| Presence of comorbiditya | |
| Yes | 183 (60.2) |
| Respiratory disease | 50 (16.4) |
| Cardiovascular disease | 45 (14.8) |
| Hepatic disease | 21 (6.9) |
| Renal disease | 18 (5.9) |
| Other | 142 (46.7) |
| Unknown | 1 (0.3) |
| Renal impairment | |
| Yes | 32 (10.5) |
| Unknown | 1 (0.3) |
| Hepatic impairment | |
| Yes | 25 (8.2) |
| Unknown | 1 (0.3) |
SD standard deviation, min minimum, max maximum
aOne subject was counted more than once
b unless otherwise specified